AU657498B2
(en)
*
|
1990-12-14 |
1995-03-16 |
Novartis Ag |
Biphenylyl compounds
|
EP0528762B1
(de)
*
|
1991-08-15 |
1997-05-07 |
Novartis AG |
N-Acyl-N-Heterocyclyl- oder Naphthylalkyl-Aminosäuren als Angiotensin II Antagonisten
|
US5260325A
(en)
*
|
1991-08-19 |
1993-11-09 |
E. I. Du Pont De Nemours And Company |
Angiotensin II receptor blocking tertiary amides
|
US5252753A
(en)
*
|
1991-11-01 |
1993-10-12 |
Ortho Pharmaceutical Corporation |
Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof
|
US5378701A
(en)
*
|
1991-12-27 |
1995-01-03 |
Kyowa Hakko Kogyo |
Tricyclic compounds
|
EP0549352B1
(en)
*
|
1991-12-27 |
2000-03-01 |
Kyowa Hakko Kogyo Co., Ltd. |
Tricyclic compounds as angiotensin II antagonists
|
ZA931063B
(en)
*
|
1992-02-17 |
1993-09-23 |
Ciba Geigy |
Treatment of glaucoma.
|
US5378715A
(en)
*
|
1992-02-24 |
1995-01-03 |
Bristol-Myers Squibb Co. |
Sulfonamide endothelin antagonists
|
US5514696A
(en)
*
|
1992-05-06 |
1996-05-07 |
Bristol-Myers Squibb Co. |
Phenyl sulfonamide endothelin antagonists
|
US5312820A
(en)
*
|
1992-07-17 |
1994-05-17 |
Merck & Co., Inc. |
Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
|
US5420123A
(en)
*
|
1992-12-21 |
1995-05-30 |
Bristol-Myers Squibb Company |
Dibenzodiazepine endothelin antagonists
|
US5256658A
(en)
*
|
1993-01-15 |
1993-10-26 |
Ortho Pharmaceutical Corporation |
Angiotensin II inhibitors
|
FR2711367B1
(fr)
*
|
1993-10-19 |
1995-12-01 |
Roussel Uclaf |
Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
|
US5965732A
(en)
*
|
1993-08-30 |
1999-10-12 |
Bristol-Myers Squibb Co. |
Sulfonamide endothelin antagonists
|
CN1143908A
(zh)
*
|
1994-03-17 |
1997-02-26 |
西巴-盖尔基股份公司 |
利用哇尔沙通(valsartan)治疗糖尿病型肾病
|
JPH0853424A
(ja)
*
|
1994-08-11 |
1996-02-27 |
Kureha Chem Ind Co Ltd |
ベンズイミダゾールスルホン酸アミド誘導体
|
US5612359A
(en)
*
|
1994-08-26 |
1997-03-18 |
Bristol-Myers Squibb Company |
Substituted biphenyl isoxazole sulfonamides
|
US5760038A
(en)
*
|
1995-02-06 |
1998-06-02 |
Bristol-Myers Squibb Company |
Substituted biphenyl sulfonamide endothelin antagonists
|
US5780473A
(en)
*
|
1995-02-06 |
1998-07-14 |
Bristol-Myers Squibb Company |
Substituted biphenyl sulfonamide endothelin antagonists
|
US5846990A
(en)
*
|
1995-07-24 |
1998-12-08 |
Bristol-Myers Squibb Co. |
Substituted biphenyl isoxazole sulfonamides
|
AU7213296A
(en)
*
|
1995-10-06 |
1997-04-30 |
Ciba-Geigy Ag |
At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
|
JPH09124620A
(ja)
|
1995-10-11 |
1997-05-13 |
Bristol Myers Squibb Co |
置換ビフェニルスルホンアミドエンドセリン拮抗剤
|
WO1997030036A1
(en)
*
|
1996-02-15 |
1997-08-21 |
Novartis Ag |
Aryl derivatives
|
US5856507A
(en)
*
|
1997-01-21 |
1999-01-05 |
Bristol-Myers Squibb Co. |
Methods for the preparation of biphenyl isoxazole sulfonamides
|
SG87052A1
(en)
|
1996-02-20 |
2002-03-19 |
Bristol Myers Squibb Co |
Pinacol ester intermediates useful for the preparation of biphenyl isoxazole sulfonamides
|
AU1791497A
(en)
|
1996-02-29 |
1997-09-16 |
Novartis Ag |
At1 receptor antagonist for the stimulation of apoptosis
|
US5939446A
(en)
*
|
1996-04-09 |
1999-08-17 |
Bristol-Myers Squibb Co. |
Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
|
KR980002035A
(ko)
*
|
1996-06-17 |
1998-03-30 |
손경식 |
비페닐 유도체 및 그의 제조방법 및 그를 함유한 약제 조성물
|
GB9613470D0
(en)
*
|
1996-06-27 |
1996-08-28 |
Ciba Geigy Ag |
Small solid oral dosage form
|
WO1998033781A1
(en)
*
|
1997-01-30 |
1998-08-06 |
Bristol-Myers Squibb Company |
Method for preventing or treating low renin hypertension by administering an endothelin antagonist
|
TW536540B
(en)
*
|
1997-01-30 |
2003-06-11 |
Bristol Myers Squibb Co |
Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
|
US6187796B1
(en)
|
1998-06-03 |
2001-02-13 |
Gpi Nil Holdings, Inc. |
Sulfone hair growth compositions and uses
|
US20010049381A1
(en)
|
1997-06-04 |
2001-12-06 |
Gpl Nil Holdings, Inc., |
Pyrrolidine derivative hair growth compositions and uses
|
US5945441A
(en)
|
1997-06-04 |
1999-08-31 |
Gpi Nil Holdings, Inc. |
Pyrrolidine carboxylate hair revitalizing agents
|
US6274602B1
(en)
|
1998-06-03 |
2001-08-14 |
Gpi Nil Holdings, Inc. |
Heterocyclic thioester and ketone hair growth compositions and uses
|
US6187784B1
(en)
|
1998-06-03 |
2001-02-13 |
Gpi Nil Holdings, Inc. |
Pipecolic acid derivative hair growth compositions and uses
|
US6271244B1
(en)
|
1998-06-03 |
2001-08-07 |
Gpi Nil Holdings, Inc. |
N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
|
US6172087B1
(en)
|
1998-06-03 |
2001-01-09 |
Gpi Nil Holding, Inc. |
N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
|
US6429215B1
(en)
|
1998-06-03 |
2002-08-06 |
Gpi Nil Holdings, Inc. |
N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
|
US6331537B1
(en)
|
1998-06-03 |
2001-12-18 |
Gpi Nil Holdings, Inc. |
Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
|
CN1295561A
(zh)
|
1998-06-03 |
2001-05-16 |
Gpinil控股公司 |
N-杂环羧酸或羧酸等排物的n-结合氨磺酰
|
AU760663B2
(en)
*
|
1998-06-03 |
2003-05-22 |
Gpi Nil Holdings, Inc. |
Small molecule sulfonamide hair growth compositions and uses
|
US6638937B2
(en)
|
1998-07-06 |
2003-10-28 |
Bristol-Myers Squibb Co. |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
AU767456B2
(en)
*
|
1998-07-06 |
2003-11-13 |
Bristol-Myers Squibb Company |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
US6204281B1
(en)
|
1998-07-10 |
2001-03-20 |
Novartis Ag |
Method of treatment and pharmaceutical composition
|
SK285863B6
(sk)
*
|
1998-07-10 |
2007-10-04 |
Novartis Ag |
Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
|
US6465502B1
(en)
*
|
1998-12-23 |
2002-10-15 |
Novartis Ag |
Additional therapeutic use
|
WO2000038676A1
(en)
|
1998-12-23 |
2000-07-06 |
Novartis Ag |
Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
|
EP1013273A1
(en)
*
|
1998-12-23 |
2000-06-28 |
Novartis AG |
Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
|
CN101011390A
(zh)
*
|
1999-01-26 |
2007-08-08 |
诺瓦提斯公司 |
血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
|
PE20001456A1
(es)
|
1999-02-02 |
2001-01-28 |
Smithkline Beecham Corp |
Compuestos calcioliticos
|
HUP0201320A2
(en)
|
1999-03-19 |
2002-08-28 |
Bristol Myers Squibb Co |
Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
|
US6395728B2
(en)
|
1999-07-08 |
2002-05-28 |
Novartis Ag |
Method of treatment and pharmaceutical composition
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
JP4374102B2
(ja)
*
|
1999-09-24 |
2009-12-02 |
住友化学株式会社 |
N,n−ジイソプロピルエチルアミンの分離方法
|
US6417189B1
(en)
|
1999-11-12 |
2002-07-09 |
Gpi Nil Holdings, Inc. |
AZA compounds, pharmaceutical compositions and methods of use
|
US7253169B2
(en)
|
1999-11-12 |
2007-08-07 |
Gliamed, Inc. |
Aza compounds, pharmaceutical compositions and methods of use
|
AU2092601A
(en)
*
|
1999-12-15 |
2001-06-25 |
Bristol-Myers Squibb Company |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
AU1464101A
(en)
|
1999-12-21 |
2001-07-03 |
Gpi Nil Holdings, Inc. |
Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
|
BR0111868A
(pt)
*
|
2000-06-22 |
2003-07-01 |
Novartis Ag |
Composições farmacêuticas
|
US20020132839A1
(en)
*
|
2000-06-22 |
2002-09-19 |
Ganter Sabina Maria |
Tablet formulations comprising valsartan
|
CA2415962C
(en)
*
|
2000-07-19 |
2010-07-06 |
Novartis Ag |
Valsartan salts
|
AR033390A1
(es)
|
2000-08-22 |
2003-12-17 |
Novartis Ag |
Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
|
US20060089389A1
(en)
*
|
2000-08-22 |
2006-04-27 |
Malcolm Allison |
Combination
|
US6639082B2
(en)
|
2000-10-17 |
2003-10-28 |
Bristol-Myers Squibb Company |
Methods for the preparation of biphenyl isoxazole sulfonamides
|
US8168616B1
(en)
|
2000-11-17 |
2012-05-01 |
Novartis Ag |
Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
|
DE10059418A1
(de)
*
|
2000-11-30 |
2002-06-20 |
Aventis Pharma Gmbh |
Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
|
US7531576B2
(en)
*
|
2000-12-26 |
2009-05-12 |
Pola Chemical Industries, Inc. |
Biphenyl derivatives
|
NZ528216A
(en)
*
|
2001-02-24 |
2006-12-22 |
Boehringer Ingelheim Pharma |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
HUP0401696A2
(hu)
*
|
2001-08-28 |
2004-11-29 |
Sankyo Co., Ltd. |
Angiotenzin-II receptor antagonistát tartalmazó gyógyászati készítmény
|
US7468390B2
(en)
|
2002-01-17 |
2008-12-23 |
Novartis Ag |
Methods of treatment and pharmaceutical composition
|
US6869970B2
(en)
*
|
2002-02-04 |
2005-03-22 |
Novartis Ag |
Crystalline salt forms of valsartan
|
EP2266590A3
(en)
|
2002-02-22 |
2011-04-20 |
Shire LLC |
Active agent delivery sytems and methods for protecting and administering active agents
|
AU2003223637A1
(en)
*
|
2002-04-15 |
2003-11-03 |
Dr. Reddy's Laboratories Limited |
Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
|
US20040072886A1
(en)
*
|
2002-04-15 |
2004-04-15 |
Dr. Reddy's Laboratories Limited |
Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan)
|
EG24716A
(en)
*
|
2002-05-17 |
2010-06-07 |
Novartis Ag |
Combination of organic compounds
|
AP2005003232A0
(en)
|
2002-08-19 |
2005-03-31 |
Pfizer Prod Inc |
Combination therapy for hyperproliferative diseases.
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
GB0222056D0
(en)
*
|
2002-09-23 |
2002-10-30 |
Novartis Ag |
Process for the manufacture of organic compounds
|
WO2004031118A1
(ja)
|
2002-10-03 |
2004-04-15 |
Ono Pharmaceutical Co., Ltd. |
Lpa受容体拮抗剤
|
DE10335027A1
(de)
|
2003-07-31 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Angiotensin II Rezeptor Antagonisten
|
CA2519490A1
(en)
*
|
2003-03-17 |
2004-09-30 |
Teva Pharmaceutical Industries Ltd |
Polymorphis of valsartan
|
EP1950204A1
(en)
|
2003-03-17 |
2008-07-30 |
Teva Pharmaceutical Industries Ltd. |
Amorphous form of valsartan
|
US7199144B2
(en)
|
2003-04-21 |
2007-04-03 |
Teva Pharmaceuticals Industries, Ltd. |
Process for the preparation of valsartan and intermediates thereof
|
US20050165075A1
(en)
*
|
2003-03-31 |
2005-07-28 |
Hetero Drugs Limited |
Novel amorphous form of valsartan
|
US7010633B2
(en)
*
|
2003-04-10 |
2006-03-07 |
International Business Machines Corporation |
Apparatus, system and method for controlling access to facilities based on usage classes
|
WO2004094392A1
(en)
*
|
2003-04-21 |
2004-11-04 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of valsartan
|
EP1556363A2
(en)
*
|
2003-04-21 |
2005-07-27 |
Teva Pharmaceutical Industries Limited |
Process for the preparation of valsartan and intermediates thereof
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
CZ298685B6
(cs)
*
|
2003-05-15 |
2007-12-19 |
Zentiva, A.S. |
Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu)
|
GEP20084406B
(en)
*
|
2003-05-30 |
2008-06-25 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives and their use as hmg-co inhibitors
|
US7361770B2
(en)
*
|
2003-06-16 |
2008-04-22 |
Hetero Drugs Limited |
Process for preparation of valsartan
|
GB0316546D0
(en)
|
2003-07-15 |
2003-08-20 |
Novartis Ag |
Process for the manufacture of organic compounds
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
WO2005021535A2
(en)
*
|
2003-08-27 |
2005-03-10 |
Zentiva, A.S. |
A method of removing the triphenylmethane protecting group
|
JP2007504136A
(ja)
*
|
2003-08-28 |
2007-03-01 |
ニトロメッド インコーポレーティッド |
ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
|
JP4537678B2
(ja)
*
|
2003-09-04 |
2010-09-01 |
住友化学株式会社 |
2’−(1h−テトラゾール−5−イル)ビフェニル−4−カルボアルデヒド結晶およびその製造方法
|
DE602004012763T2
(de)
*
|
2003-10-10 |
2009-05-07 |
Solvay Pharmaceuticals Gmbh |
Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker
|
WO2005051298A2
(en)
|
2003-11-19 |
2005-06-09 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
WO2005049587A1
(en)
*
|
2003-11-21 |
2005-06-02 |
Ranbaxy Laboratories Limited |
Process for preparation of biphenyl tetrazole
|
ITMI20032267A1
(it)
*
|
2003-11-21 |
2005-05-22 |
Dinamite Dipharma S P A In Forma A Bbreviata Diph |
Procdimento per la preparzione di valsartan e suoi intermedi
|
HRP20030965A2
(en)
*
|
2003-11-24 |
2005-08-31 |
Belupo - Lijekovi I Kozmetika D.D. |
Process for production of (s)-n-pentanoyl-n-[[2'-(
|
GB0327839D0
(en)
|
2003-12-01 |
2003-12-31 |
Novartis Ag |
Organic compounds
|
GB0402262D0
(en)
|
2004-02-02 |
2004-03-10 |
Novartis Ag |
Process for the manufacture of organic compounds
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
US20080161321A1
(en)
|
2004-03-17 |
2008-07-03 |
David Louis Feldman |
Use of Renin Inhibitors in Therapy
|
ES2251292B1
(es)
|
2004-04-20 |
2007-07-01 |
Inke, S.A. |
Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
|
JP4793692B2
(ja)
*
|
2004-04-26 |
2011-10-12 |
小野薬品工業株式会社 |
新規なblt2介在性疾患、blt2結合剤および化合物
|
CZ298471B6
(cs)
*
|
2004-05-19 |
2007-10-10 |
Zentiva, A.S. |
Soli benzylesteru N-[(2´-(1H-tetrazol-5-yl)bifenyl-4-yl)methyl]-(L)-valinu a jejich použití pro výrobu valsartanu
|
US20080255111A1
(en)
*
|
2004-07-02 |
2008-10-16 |
Sankyo Company Limited |
Tissue Factor Production Inhibitor
|
KR20130048281A
(ko)
|
2004-10-08 |
2013-05-09 |
노파르티스 아게 |
확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를 위한 레닌 억제제의 용도
|
KR101021828B1
(ko)
|
2004-10-27 |
2011-03-17 |
다이이찌 산쿄 가부시키가이샤 |
2 이상의 치환기를 갖는 벤젠 화합물
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
EP1838681A2
(en)
|
2004-12-22 |
2007-10-03 |
Enantia, S.L. |
Intermediate compounds for the preparation of an angiotensin ii receptor and process for the preparation of valsartan
|
EP2033629B1
(en)
*
|
2004-12-24 |
2012-11-14 |
Krka |
Solid pharmaceutical composition comprising valsartan
|
US7659406B2
(en)
*
|
2005-01-03 |
2010-02-09 |
Dr. Reddy's Laboratories Limited |
Process for preparing valsartan
|
JP2007527924A
(ja)
*
|
2005-01-11 |
2007-10-04 |
テバ ファーマシューティカル インダストリーズ リミティド |
非晶質バルサルタンの製造方法
|
US20060281801A1
(en)
*
|
2005-04-19 |
2006-12-14 |
Ashok Kumar |
Process for the preparation of valsartan and its intermediates
|
EP1896433A4
(en)
*
|
2005-05-25 |
2010-06-02 |
Ipca Lab Ltd |
NOVEL CRYSTALLINE FORMS OF (S) -N- (1-CARBOXY-2-METHYL-PROP-1-YL) -N-PENTANOYL-N- [2 '- (1H-TETRAZOL-5-YL) BI-PHENYL-4 ylmethyl] amine
|
WO2007005967A2
(en)
*
|
2005-07-05 |
2007-01-11 |
Teva Pharmaceutical Industries Ltd. |
Process for preparing valsartan
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
AT502219B1
(de)
*
|
2005-08-04 |
2007-04-15 |
Sanochemia Pharmazeutika Ag |
Verfahren zur reindarstellung von 5-substituierten tetrazolen
|
EP1922069A2
(en)
*
|
2005-08-08 |
2008-05-21 |
Nitromed, Inc. |
Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use
|
JP2009504800A
(ja)
*
|
2005-08-22 |
2009-02-05 |
アレンビク リミテッド |
バルサルタンの調製方法
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
WO2007057919A2
(en)
*
|
2005-10-25 |
2007-05-24 |
Alembic Limited |
An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
|
WO2007052307A2
(en)
*
|
2005-10-31 |
2007-05-10 |
Lupin Limited |
Stable solid oral dosage forms of valsartan
|
AU2006313430B2
(en)
*
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
AR057882A1
(es)
*
|
2005-11-09 |
2007-12-26 |
Novartis Ag |
Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
|
RU2459809C2
(ru)
*
|
2005-11-09 |
2012-08-27 |
Новартис Аг |
Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US20070141533A1
(en)
*
|
2005-12-20 |
2007-06-21 |
Ford Christopher W |
Polymeric dental implant assembly
|
US20070166372A1
(en)
*
|
2006-01-19 |
2007-07-19 |
Mai De Ltd. |
Preparation of solid coprecipitates of amorphous valsartan
|
WO2007088558A2
(en)
*
|
2006-02-02 |
2007-08-09 |
Alembic Limited |
A process for purification of valsartan
|
WO2008020314A2
(en)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Statin stabilizing dosage formulations
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
EA030606B1
(ru)
|
2006-05-04 |
2018-08-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способы приготовления лекарственного средства, содержащего полиморфы
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
WO2007132307A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
CZ300801B6
(cs)
*
|
2006-06-07 |
2009-08-12 |
Helvetia Pharma A.S. |
Kompozice s valsartanem v pevných lékových formách
|
WO2008035364A2
(en)
*
|
2006-06-23 |
2008-03-27 |
Usv Limited |
Process for the preparation of micronized valsartan
|
US20080004313A1
(en)
*
|
2006-06-28 |
2008-01-03 |
Mai De Ltd. |
Preparation of crystalline polymorphs of rimonabant hydrochloride
|
EP2057132A2
(en)
*
|
2006-07-03 |
2009-05-13 |
Aurobindo Pharma Limited |
Process for the preparation of the angiotensin ii antagonist valsartan
|
AU2007274724B2
(en)
*
|
2006-07-14 |
2012-07-26 |
Ranbaxy Laboratories Limited |
Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
|
CN101528691B
(zh)
|
2006-08-22 |
2014-11-26 |
兰贝克赛实验室有限公司 |
基质金属蛋白酶抑制剂
|
EP1908469A1
(en)
|
2006-10-06 |
2008-04-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
|
US8404896B2
(en)
|
2006-12-01 |
2013-03-26 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
US20100217008A1
(en)
*
|
2006-12-14 |
2010-08-26 |
Ratiopharm Gmbh |
Process for the preparation of valsartan and intermediate products
|
LT2121578T
(lt)
|
2007-01-12 |
2016-11-25 |
Novartis Ag |
5-bifenil-4-amino-2-metilpentano rūgšties gavimo būdas
|
TW200838501A
(en)
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
ZA200905537B
(en)
|
2007-03-01 |
2010-10-27 |
Probiodrug Ag |
New use of glutaminyl cyclase inhibitors
|
WO2008120242A1
(en)
*
|
2007-03-29 |
2008-10-09 |
Alembic Limited |
Valsartan tablet formulations
|
JP5667440B2
(ja)
|
2007-04-18 |
2015-02-12 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
|
TWI448284B
(zh)
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
KR20100021433A
(ko)
*
|
2007-05-07 |
2010-02-24 |
시플라 리미티드 |
발사르탄의 제조방법
|
US20080299218A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Protia, Llc |
Deuterium-enriched valsartan
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
TWI406850B
(zh)
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
ES2312162T3
(es)
*
|
2007-06-07 |
2009-02-16 |
Inke, S.A. |
Procedimiento para la obtencion de una sal de valsartan util para la preparacion de valsartan.
|
WO2009001375A2
(en)
*
|
2007-06-27 |
2008-12-31 |
Matrix Laboratories Ltd |
Improved process for preparing pure valsartan
|
GB0715628D0
(en)
*
|
2007-08-10 |
2007-09-19 |
Generics Uk Ltd |
Solid valsartan composition
|
KR101610005B1
(ko)
*
|
2007-08-17 |
2016-04-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체
|
US7834041B2
(en)
|
2007-09-07 |
2010-11-16 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
EP2209786B1
(en)
*
|
2007-10-05 |
2013-02-27 |
Verastem, Inc. |
Pyrimidine substituted purine derivatives
|
EP2197416A1
(en)
|
2007-10-09 |
2010-06-23 |
Novartis Ag |
Pharmaceutical formulation of valsartan
|
WO2009064681A2
(en)
|
2007-11-12 |
2009-05-22 |
Novartis Ag |
Liquid compositions comprising valsartan
|
US8212052B2
(en)
|
2007-12-11 |
2012-07-03 |
Theravance, Inc. |
Dual-acting benzoimidazole antihypertensive agents
|
BRPI0821455A2
(pt)
*
|
2007-12-31 |
2015-06-16 |
Lupin Ltd |
Composições farmacêuticas de amlopidina e valsartan
|
EP2090567A3
(en)
|
2008-02-13 |
2011-06-01 |
Ranbaxy Laboratories Limited |
Processes for the preparation of intermediates of valsartan
|
US20090226515A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
US20090226516A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Sartan compositions
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2260018A2
(en)
*
|
2008-04-07 |
2010-12-15 |
Hetero Research Foundation |
Process for preparation of valsartan intermediate
|
JP2011518884A
(ja)
|
2008-04-29 |
2011-06-30 |
セラヴァンス, インコーポレーテッド |
二重活性抗高血圧剤
|
KR100995734B1
(ko)
|
2008-05-28 |
2010-11-19 |
일동제약주식회사 |
발사르탄의 개선된 제조방법
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
EP3239170B1
(en)
|
2008-06-04 |
2019-03-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2334651A2
(en)
|
2008-07-24 |
2011-06-22 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
EA031225B1
(ru)
*
|
2008-08-15 |
2018-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Ингибиторы дпп-4 для заживления ран
|
CN101362728B
(zh)
*
|
2008-08-22 |
2011-07-20 |
北京赛科药业有限责任公司 |
一种缬沙坦的合成方法
|
EP2344195A2
(en)
|
2008-09-10 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Combination therapy for the treatment of diabetes and related conditions
|
BRPI0920330A2
(pt)
*
|
2008-10-10 |
2016-02-23 |
Janssen Pharmaceutica Nv |
terapia de combinação que compreende bloqueadores do receptor da angiotensina e antagonistas do receptor da vasopressina
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
EP2194048A1
(en)
|
2008-12-02 |
2010-06-09 |
Dirk Sartor |
Nitrate esters for the treatment of vascular and metabolic diseases
|
KR101012135B1
(ko)
|
2008-12-18 |
2011-02-07 |
주식회사 대희화학 |
발사르탄 메틸 에스테르의 제조방법
|
WO2010075347A2
(en)
|
2008-12-23 |
2010-07-01 |
Takeda Pharmaceutical Company Limited |
Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
|
BRPI0923121A2
(pt)
|
2008-12-23 |
2015-08-11 |
Boehringer Ingelheim Int |
Formas salinas de compostos orgânico
|
CN101768128B
(zh)
*
|
2009-01-05 |
2012-10-10 |
浙江华海药业股份有限公司 |
一种含10%以上异构体的缬沙坦的精制方法
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
CN101475540B
(zh)
*
|
2009-01-22 |
2011-05-11 |
江苏德峰药业有限公司 |
一种缬沙坦的制备方法
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
US7956054B2
(en)
|
2009-07-07 |
2011-06-07 |
Theravance, Inc. |
Dual-acting pyrazole antihypertensive agents
|
EP2456762B1
(en)
|
2009-07-22 |
2013-10-16 |
Theravance, Inc. |
Dual-acting oxazole antihypertensive agents
|
MX2012002993A
(es)
|
2009-09-11 |
2012-04-19 |
Probiodrug Ag |
Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
|
EP2316821A1
(en)
*
|
2009-10-27 |
2011-05-04 |
Novartis AG |
Process for the manufacture of organic compounds
|
ES2760917T3
(es)
|
2009-11-27 |
2020-05-18 |
Boehringer Ingelheim Int |
Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
|
US8481549B2
(en)
*
|
2010-01-19 |
2013-07-09 |
Theravance, Inc. |
Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
|
KR101152144B1
(ko)
*
|
2010-02-01 |
2012-06-15 |
경동제약 주식회사 |
발사르탄의 제조 방법 및 이에 사용되는 신규 중간체
|
EP2536396B1
(en)
|
2010-02-16 |
2016-08-10 |
KRKA, D.D., Novo Mesto |
Process for the preparation of oral solid dosage forms comprising valsartan
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
MX2012010470A
(es)
|
2010-03-10 |
2012-10-09 |
Probiodrug Ag |
Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
|
EP2556059B1
(en)
*
|
2010-04-07 |
2014-05-07 |
KRKA, d.d., Novo mesto |
Improved process for preparing valsartan
|
CN103080095A
(zh)
|
2010-04-19 |
2013-05-01 |
心脏林克斯股份公司 |
用于治疗血管和代谢疾病的携带氮氧化物给体的缬沙坦衍生物
|
US8541596B2
(en)
|
2010-04-21 |
2013-09-24 |
Probiodrug Ag |
Inhibitors
|
JP6034781B2
(ja)
|
2010-05-05 |
2016-11-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
併用療法
|
EA201991014A1
(ru)
|
2010-06-24 |
2019-09-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение диабета
|
WO2012001484A2
(en)
|
2010-07-02 |
2012-01-05 |
Aurobindo Pharma Limited |
An improved process for the preparation of valsartan
|
TR201005419A2
(tr)
|
2010-07-05 |
2012-01-23 |
Bi̇lgi̇ç Mahmut |
Valsartan içeren farmasötik bileşim.
|
SG187007A1
(en)
|
2010-08-03 |
2013-02-28 |
Novartis Ag |
Highly crystalline valsartan
|
KR101476937B1
(ko)
|
2010-08-23 |
2014-12-24 |
노파르티스 아게 |
Nep 억제제의 제조를 위한 중간체의 제조 방법
|
ES2702529T3
(es)
|
2010-08-24 |
2019-03-01 |
Novartis Ag |
Una composición farmacéutica para uso en la prevención o tratamiento de la insuficiencia cardíaca en un mamífero que recibe terapia anticoagulante
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012056294A1
(en)
|
2010-10-29 |
2012-05-03 |
Jubilant Life Sciences Ltd. |
An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
US8449890B2
(en)
*
|
2011-02-17 |
2013-05-28 |
Theravance, Inc. |
Neprilysin inhibitors
|
WO2012123563A1
(en)
|
2011-03-16 |
2012-09-20 |
Probiodrug Ag |
Benz imidazole derivatives as inhibitors of glutaminyl cyclase
|
FR2977253B1
(fr)
|
2011-06-30 |
2013-08-09 |
Centre Nat Rech Scient |
Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene
|
MX366629B
(es)
|
2011-07-15 |
2019-07-17 |
Boehringer Ingelheim Int |
Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
|
WO2013022243A2
(ko)
*
|
2011-08-05 |
2013-02-14 |
동국대학교 산학협력단 |
신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
WO2013030725A1
(en)
|
2011-08-26 |
2013-03-07 |
Wockhardt Limited |
Methods for treating cardiovascular disorders
|
WO2013090196A1
(en)
|
2011-12-15 |
2013-06-20 |
Takeda Pharmaceuticals U.S.A., Inc. |
Combinations of azilsartan and chlorthalidone for treating hypertension black patients
|
EP2797580A2
(en)
|
2011-12-26 |
2014-11-05 |
Novartis AG |
Tablets and dry-coated agents
|
WO2013098578A1
(en)
|
2011-12-31 |
2013-07-04 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
|
WO2013098576A1
(en)
|
2011-12-31 |
2013-07-04 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Immediate release pharmaceutical composition of valsartan
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013163758A1
(en)
|
2012-05-01 |
2013-11-07 |
Boyd Shelley Romayne |
Methods for treating and diagnosing blinding eye diseases
|
EP3685839A1
(en)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin for use in the treatment of albuminuria and kidney related diseases
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
CA2882771C
(en)
|
2012-08-24 |
2021-02-23 |
Novartis Ag |
Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
|
WO2014118721A1
(en)
|
2013-01-30 |
2014-08-07 |
Ranbaxy Laboratories Limited |
Pharmaceutical oral solid dosage forms comprising valsartan and nebivolol
|
CN105163734A
(zh)
|
2013-03-12 |
2015-12-16 |
株式会社Lg生命科学 |
包含缬沙坦及罗舒伐他汀钙的复合制剂及其制造方法
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
BR112015026513A2
(pt)
|
2013-04-17 |
2017-07-25 |
Pfizer |
derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
PL3626270T3
(pl)
|
2013-08-26 |
2024-04-08 |
Novartis Ag |
Leczenie chorób sercowo-naczyniowych
|
US20160206597A1
(en)
|
2013-08-26 |
2016-07-21 |
Toni Lynne Bransford |
New Use
|
WO2015056219A1
(en)
|
2013-10-18 |
2015-04-23 |
Ranbaxy Laboratories Limited |
Process for simultaneous drying and micronization of valsartan
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
CN103923028B
(zh)
*
|
2014-05-04 |
2017-05-24 |
青岛雪洁助剂有限公司 |
一种缬沙坦甲酯的制备方法
|
CN104072386A
(zh)
*
|
2014-06-28 |
2014-10-01 |
浙江华海药业股份有限公司 |
一种缬沙坦中间体的改进方法
|
CN106414416B
(zh)
*
|
2014-09-09 |
2020-03-27 |
上海翰森生物医药科技有限公司 |
结晶型ARB-NEPi复合物及其制备方法和应用
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
JP6382736B2
(ja)
*
|
2015-02-02 |
2018-08-29 |
株式会社トクヤマ |
バルサルタンの製造方法
|
PT3294283T
(pt)
|
2015-05-11 |
2023-06-07 |
Novartis Ag |
Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca
|
EP3302460A1
(en)
|
2015-05-29 |
2018-04-11 |
Novartis AG |
Sacubitril and valsartan for treating metabolic disease
|
EP3828175A1
(en)
|
2015-06-12 |
2021-06-02 |
Teva Pharmaceuticals International GmbH |
Solid state forms of trisodium valsartan: sacubitril
|
WO2017006254A1
(en)
|
2015-07-08 |
2017-01-12 |
Novartis Ag |
Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
|
CN113750102A
(zh)
|
2015-07-23 |
2021-12-07 |
拜耳制药股份公司 |
可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途
|
US10596151B2
(en)
|
2015-08-28 |
2020-03-24 |
Novartis Ag |
Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
|
CN108601741B
(zh)
|
2016-02-03 |
2022-05-24 |
诺华股份有限公司 |
有机化合物的盖伦制剂
|
JP2019517542A
(ja)
|
2016-06-10 |
2019-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
リナグリプチンおよびメトホルミンの組合せ
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
US10745363B2
(en)
|
2016-09-02 |
2020-08-18 |
Nanjing Noratech Pharmaceuticals Co., Ltd |
Crystal forms of valsartan disodium salt
|
CN107056720A
(zh)
*
|
2016-12-30 |
2017-08-18 |
湖南千金湘江药业股份有限公司 |
一种缬沙坦的制备和纯化方法
|
EP3342400A1
(en)
|
2016-12-31 |
2018-07-04 |
Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. |
A pharmaceutical composition comprising valsartan and chlorthalidone
|
WO2018153895A1
(de)
|
2017-02-22 |
2018-08-30 |
Bayer Pharma Aktiengesellschaft |
Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
|
EA202090205A1
(ru)
|
2017-07-07 |
2020-06-02 |
Бёрингер Ингельхайм Ветмедика Гмбх |
Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов
|
PL3658122T3
(pl)
|
2017-07-28 |
2021-10-18 |
Synthon B.V. |
Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
|
EP3461819B1
(en)
|
2017-09-29 |
2020-05-27 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
EP3498698A1
(en)
|
2017-12-15 |
2019-06-19 |
Mankind Pharma Ltd |
Solid forms of valsartan disodium and process of preparation thereof
|
CA3096838A1
(en)
|
2018-04-11 |
2019-10-17 |
Ohio State Innovation Foundation |
Methods and compositions for sustained release microparticles for ocular drug delivery
|
EP3807898A1
(en)
|
2018-06-14 |
2021-04-21 |
AstraZeneca UK Limited |
Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
|
US20210177803A1
(en)
|
2018-08-23 |
2021-06-17 |
Novartis Ag |
New pharmaceutical use for the treatment of heart failure
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
US10478422B1
(en)
|
2018-12-14 |
2019-11-19 |
ECI Pharmaceuticals, LLC |
Oral liquid compositions including valsartan
|
US10548838B1
(en)
|
2018-12-14 |
2020-02-04 |
ECI Pharmaceuticals, LLC |
Oral liquid compositions including valsartan
|
US11413275B1
(en)
|
2018-12-14 |
2022-08-16 |
ECI Pharmaceuticals, LLC |
Oral liquid compositions including valsartan
|
MX2021008533A
(es)
|
2019-01-18 |
2021-08-19 |
Astrazeneca Ab |
Inhibidores de la pcsk9 y metodos de uso de los mismos.
|
US11446243B1
(en)
|
2019-08-05 |
2022-09-20 |
ECI Pharmaceuticals, LLC |
Oral liquid compositions including valsartan
|
EP3939967A1
(en)
|
2020-07-15 |
2022-01-19 |
KRKA, d.d., Novo mesto |
A continuous process for the preparation of (s)-methyl n-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-n-pentanoylvalinate in a flow reactor
|
KR20220012821A
(ko)
|
2020-07-23 |
2022-02-04 |
주식회사 종근당 |
이중 작용 복합 화합물의 결정형 및 이의 제조방법
|
US11655220B2
(en)
|
2020-10-22 |
2023-05-23 |
Hetero Labs Limited |
Process for the preparation of angiotensin II receptor blockers
|
CN113387805B
(zh)
*
|
2021-07-21 |
2024-01-12 |
黑龙江立科新材料有限公司 |
基于烷基重氮盐取代反应的化合物的制备方法
|
WO2024019957A1
(en)
*
|
2022-07-18 |
2024-01-25 |
Celgene Corporation |
Compounds for the treatment of neurodegenerative diseases
|